Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00903877 · ClinicalTrials.gov registry record · NA
Study of T3 for the Treatment of Fibromyalgia
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00903877: Completed NA study, sponsored by Stanford University.
NCT00903877 is a NA study that has completed, run by Stanford University. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00903877, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using T3 (the active form of thyroid hormone) for the treatment of fibromyalgia. We specifically aim to assess the feasibility, cost, obstacles and promise of conducting a prospective controlled study in the future.
Interventions
- DRUG T3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00903877
The ClinicalTrials.gov registry entry for NCT00903877 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T3 is the first listed.
NCT00903877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00903877 about?
NCT00903877 is a clinical study titled "Study of T3 for the Treatment of Fibromyalgia". Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using T3 (the active form of thyroid hormone) for the treatment of fibromyalgia. We specifically a...
What is the current status of trial NCT00903877?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2009-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00903877?
The interventions under investigation include: T3 (DRUG).
Who is sponsoring clinical trial NCT00903877?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.